Notably, we previously showed that targeting HER3 with our newly developed monoclonal antibody 4A7 significantly enhanced the efficacy of chemotherapy in the preclinical models of TNBC, suggesting the therapeutic potential of HER3 inhibition in this aggressive subtype of breast cancer [24, 25]. The gene discussed is ERBB3; the disease is breast carcinoma.